Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| NeuroBo Pharmaceuticals Inc | NRBO | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.23 | 03:17:48 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.23 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.8888 - 6.7499 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 3.23 | USD |
NeuroBo Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 15.67M | 4.85M | - | 0 | -12.47M | -2.57 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NeuroBo Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/17/2024 | 07:05 | PR Newswire (US) | NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1.. |
| 4/01/2024 | 07:01 | PR Newswire (US) | NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of.. |
| 3/28/2024 | 07:01 | PR Newswire (US) | NeuroBo Pharmaceuticals Reports Year End 2023 Financial.. |
| 3/13/2024 | 07:01 | PR Newswire (US) | NeuroBo Pharmaceuticals Receives Safety Review Committee.. |
| 3/04/2024 | 07:01 | PR Newswire (US) | NeuroBo Pharmaceuticals Appoints Seasoned Life Science.. |
| 3/04/2024 | 06:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/29/2024 | 07:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/29/2024 | 07:01 | PR Newswire (US) | NeuroBo Pharmaceuticals Receives First Site IRB Approval for.. |
| 2/14/2024 | 07:52 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/12/2024 | 07:01 | PR Newswire (US) | NeuroBo Pharmaceuticals to Participate in the BIO CEO &.. |
| 2/01/2024 | 07:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/01/2024 | 07:01 | PR Newswire (US) | NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NRBO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.10 | 3.4999 | 2.99 | 3.09 | 22,592 | 0.13 | 4.19% |
| 1 Month | 4.05 | 4.12 | 2.99 | 3.49 | 24,127 | -0.82 | -20.25% |
| 3 Months | 4.91 | 6.7499 | 2.99 | 5.32 | 130,382 | -1.68 | -34.22% |
| 6 Months | 3.44 | 6.7499 | 2.90 | 5.32 | 708,432 | -0.21 | -6.10% |
| 1 Year | 5.2016 | 6.7499 | 2.8888 | 5.00 | 489,872 | -1.97 | -37.90% |
| 3 Years | 842.40 | 1,576.80 | 2.8888 | 260.24 | 1,038,918 | -839.17 | -99.62% |
| 5 Years | 2,196.00 | 7,200.00 | 2.8888 | 321.73 | 751,988 | -2,192.77 | -99.85% |
NeuroBo Pharmaceuticals Description
| NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19. ANA001 is being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the USA. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. |
